anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients receive oral benzoylphenylurea weekly for 6 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of benzoylphenylurea until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 6 patients experience dose-limiting toxicity.
Microvascular integrity is a critical factor in myocardial fluid homeostasis. The subtle equilibrium between capillary filtration and lymphatic fluid removal is disturbed during pathological processes leading to inflammation, but also in hypoxia or due to alterations in vascular perfusion and coagulability. The degradation of the glycocalyx as the main component of the endothelial filtration barrier as well as pericyte disintegration results in the accumulation of interstitial and intracellular water. Moreover, lymphatic dysfunction evokes an increase in metabolic waste products, cytokines and inflammatory cells in the interstitial space contributing to myocardial oedema formation. This leads to myocardial stiffness and impaired contractility, eventually resulting in cardiomyocyte apoptosis, myocardial remodelling and fibrosis. The following article reviews pathophysiological inflammatory processes leading to myocardial oedema including myocarditis, ischaemia-reperfusion injury and viral infections with a special focus on the pathomechanisms evoked by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In addition, clinical implications including potential long-term effects due to viral persistence (long COVID), as well as treatment options, are discussed.
This is a randomized, double-blind and placebo controlled trial using individualised homeopathic medicine (dynamized estrogen) to treat chronic pelvic pain of endometriosis. Patients with endometriosis, chronic pelvic pain and a set of signs and symptoms similar to those of the estrogen adverse events will be recruited in the Sector of Endometriosis of the Clinical Division of Gynaecological of the Hospital das Clínicas of the Faculty of Medicine of the University of Sao Paulo. The selection process was carried out through the analysis of medical charts and self-completing of structured questionnaires. Satisfied the inclusion criteria, fifty patients were randomly and distributed to receive dynamized estrogen or placebo. The primary clinical outcome is the severity of the chronic pelvic pain. Statistical analysis will be by intention-to-treat and per protocol comparing homeopathic drug with placebo after 24 weeks of intervention.
Subjects will receive ketoconazole 400 mg once daily on Days 1 - 7. On Day 4 subjects will receive a single dose of oral casopitant 100 mg along with ketoconazole.
FIELD: biochemistry, medicine. SUBSTANCE: products: pentapeptides of the general formula I  , where X 1 , X 2  and X 3  mean independently OH or NH 2  under condition that X 2  and X 3  both do not mean NH 2 . To synthesize compounds of the general formula I classic methods of peptide synthesis are used: in solution, on the solid phase following by removal of protected groups from amino-, amido, hydroxyl- and/or carboxyl. Synthesized compounds show capability to inhibit the growth of liver cells, they do not show any toxicity. EFFECT: improved method of synthesis. 6 tbl
As Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) are easily accessible, easy to isolate, and ethically acceptable, they represent a promising source of MSCs for use in regenerative medicine. Considering decisions on WJ-MSCs collection requires extensive knowledge of the factors that impact their yield. This study's aim was to evaluate the influence of parameters related to mothers and newborns on the WJ-MSCs yield. The WJ-MSCs were isolated and expanded after being isolated from 79 umbilical cord (UC) samples. Population doubling time and cell proliferation were assessed. By flow cytometry analysis, WJ-MSCs were identified by positivity of CD105, CD90, and CD73 and negativity of CD45 and CD34. There was a statistically significant negative correlation between UC width and P1 doubling time. Maternal age and WJ-MSC yield were shown to be negatively correlated. Birth weight and gestational age showed a significant positive correlation between WJ-MSCs yield and neonatal variables. No significant correlations were detected between the WJ-MSCs and the mother parity, nor the neonatal sex, fetal presentation, or head circumference. The WJ-MSCs yield increases with younger maternal age, higher gestational age, and increased neonatal birth weight. Hence, consideration should be given to these factors when selecting the ideal donors.
FIELD: cosmetic industry. SUBSTANCE: the suggested composition contains, in cosmetically acceptable medium, a cleansing foundation, at least, one cation polymer and, at least, one anion product of polycondensation which contains, at least, one polyurethane and/or polycarbamide block. At the same time, the mentioned product of polycondensation is water-soluble. These compositions are of improved brushing action to be applied to clean, take care of hair and make hairstyles. EFFECT: higher efficiency for hair care. 19 cl, 6 ex
The term "COPD" refers to a range of illnesses that impair breathing and obstruct airflow.

Smoking or having smoked in the past increases the risk of developing COPD because tobacco smoke is the primary cause of the disease. The risk is further increased by family history, occupational or home, air pollution exposure and respiratory illnesses including pneumonia. The signs and symptoms include wheezing, coughing up mucus (sputum) and difficulty in breathing. It is frequently brought on by prolonged exposure to irritant gases or particulates most frequently from cigarette smoke. Heart disease, lung cancer and a number of other diseases are more likely to occur in people with COPD.

A randomised controlled trial will be conducted with COPD patients as its target population. There will be 40 individuals for both the control group and the intervention group. Group A is a control group while Group B is an experimental group (20 participants on Group A and 20 on group B). The baseline treatment for both groups were pursed lip breathing and ACBT. On the other hand, group B experimental group will also undergo (pursued lip breathing and ACBT) with autogenic drainage. Group A session lasts for 30 minutes and Group B session lasts for 45 minutes. There is only one session per day. There is a three session in a week for 4 weeks. Measurements are made of dyspnea, oxygen saturation, peak expiratory flow rate, pulse rate and fatigue both before and after the treatment, data were recorded. Participants in the trial must have mild to moderate COPD (GOLD Criteria) and be between the ages of 40 to 60 years. Data from Sheikh Zayed Hospital, Rahim Yar Khan will be collected. Follow-up for both completed tasks and changes in pulmonary status will be evaluated after 4 weeks. Modified Borg Dyspnea (RPE) Scale, Breathlessness, Cough and Sputum Scale (BCSS), Fatigue Severity Scale or Visual Analogue Scale, Peak flow meter, Oximeter will be used to measure the outcomes. Data will be analysed using the SPSS 21.0 Statistical Software.
A wide range of antibacterial action is provided by the overlapping spectra of neomycin, polymyxin B sulfate, and bacitracin.

Neomycin is bactericidal for many gram-positive and gram-negative organisms. It is an aminoglycoside antibiotic which inhibits protein synthesis by binding with ribosomal RNA and causing misreading of the bacterial genetic code.

Polymyxin B is bactericidal for a variety of gram-negative organisms. It increases the permeability of the bacterial cell membrane by interacting with the phospholipid components of the membrane.

Bacitracin is bactericidal for a variety of gram-positive and gram-negative organisms. It interferes with bacterial cell wall synthesis by inhibition of the regeneration of phospholipid receptors involved in peptidoglycan synthesis.

Microbiology: Neomycin sulfate, polymyxin B sulfate and bacitracin zinc together are considered active against the following microorganisms: Staphylococcus aureus, streptococci including Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae, Klebsiella-Enterobacter species, Neisseria species, and Pseudomonas aeruginosa. The product does not provide adequate coverage against Serratia marcescens.
The invention discloses a stringy stonecrop herb pill preparation and a preparing method thereof, belonging to the technical field of medicine. The stringy stonecrop herb pill preparation is obtained by taking the stringy stonecrop herb extracted and purified matter as the main component and utilizing polyethyleneglycol 4000 and polyethyleneglycol 6000 as the combining component. The preparing method comprises the steps of heating the polyethyleneglycol on a water bath according to the composing ratio to melt the polyethyleneglycol, adding the stringy stonecrop herb extracted and purified matter, evenly mixing, adding medical anhydrous ethanol in proper quantity to assist the dissolution, preserving the temperature at 80 to 90 DEG C after the ethanol volatilizes; preheating a pill dropping machine, keeping the temperature constant in a liquid storing room at the needed temperature, adopting the whiteruss as a cooling agent, dripping in a speed of 25 to 35 drips per minute, collecting the pills, absorbing and removing the cooling agent, drying in vacuum to acquire the final product. Compared with the prior art, the stringy stonecrop herb pill dissolves completely in 5 minutes, and the pill effects rapidly. The invention has high biological utilization degree, reduces the dosage and improves the adaptability of the patients. Besides, the invention has advanced technique condition and strict quality control, the production environment is improved, the production cost is reduced and the invention is suitable for industrialized scale production.
10,460. SzÚll, K. May 1. No Patent granted (Sealing fee not paid). Medicines for internal use.-A remedy for consumption consists of calcium chlorate, tartrate of lime, blood fibrine, and guaiacol. The chlorate is neutralized with a mixture of quinine sulphate and benzoic acid, and may be replaced wholly or in part by perchlorate of calcium. The blood fibrine is softened with an alkaline lye and neutralized with hydrochloric acid. The guaiacol may be replaced by guaiacolum carbonicum or by creosote, or by the potassium salt of guaiacol sulphonic acid.
OBJECTIVE: Functional seizures (FS) look like epileptic seizures but are characterized by a lack of epileptic activity in the brain. Approximately one in five referrals to epilepsy clinics are diagnosed with this condition. FS are diagnosed by recording a seizure using video-electroencephalography (EEG), from which an expert inspects the semiology and the EEG. However, this method can be expensive and inaccessible and can present significant patient burden. No single biomarker has been found to diagnose FS. However, the current limitations in FS diagnosis could be improved with machine learning to classify signal features extracted from EEG, thus providing a potentially very useful aid to clinicians.
METHODS: The current study has investigated the use of seizure-free EEG signals with machine learning to identify subjects with FS from those with epilepsy. The dataset included interictal and preictal EEG recordings from 48 subjects with FS (mean age = 34.76 ± 10.55 years, 14 males) and 29 subjects with epilepsy (mean age = 38.95 ± 13.93 years, 18 males) from which various statistical, temporal, and spectral features from the five EEG frequency bands were extracted then analyzed with threshold accuracy, five machine learning classifiers, and two feature importance approaches.
RESULTS: The highest classification accuracy reported from thresholding was 60.67%. However, the temporal features were the best performing, with the highest balanced accuracy reported by the machine learning models: 95.71% with all frequency bands combined and a support vector machine classifier.
SIGNIFICANCE: Machine learning was much more effective than using individual features and could be a powerful aid in FS diagnosis. Furthermore, combining the frequency bands improved the accuracy of the classifiers in most cases, and the lowest performing EEG bands were consistently delta and gamma.
Isorhapontigenin (ISO), a naturally-occurring stilbene derivative, has garnered significant attention due to its potent anticancer and anti-inflammatory properties. This review synthesizes current knowledge regarding the mechanisms of action, efficacy, and potential therapeutic applications of Isorhapontigenin acquired in vitro and in vivo. It systematically analyzes its effects on various cancer cell lines, tumor models, and inflammatory conditions, examining its impact on cell proliferation, apoptosis, metastasis, and inflammatory mediators. In vitro studies reveal that Isorhapontigenin induces cell cycle arrest, promotes apoptosis, and inhibits cancer cell migration through modulation of key signaling pathways, including EGFR-PI3K-Akt and NF-κB. It also demonstrates potent antioxidant and anti-inflammatory effects by enhancing Nrf2 signaling and suppressing pro-inflammatory cytokine production. These findings are corroborated by in vivo studies confirming its ability to inhibit tumor growth in xenograft models and attenuate inflammatory responses in various disease models. Notably, Isorhapontigenin exhibits superior pharmacokinetic profiles then resveratrol, with higher oral bioavailability. Isorhapontigenin demonstrates multi-target actions, including epigenetic modulation through microRNA regulation, which highlight its potential as a versatile therapeutic agent. This review also identifies current limitations in Isorhapontigenin research that require further investigation. Overall, Isorhapontigenin offers promise as a multi-faceted compound for the treatment of cancer, inflammatory diseases, and metabolic disorders, providing a solid foundation for future research and potential clinical applications.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to pharmacogenetics, clinical pharmacology, psychiatry, addictology, and can be used for selecting the fluvoxamine antidepressant dose. What is described is a method for predicting the clinical effectiveness of fluvoxamine therapy for treating disorders accompanied by development of depressive symptoms by genotyping using polymorphic markers of CYP2D6 genes. Value of the parameter P is calculated, which is the estimated value of change in the rate of biotransformation of fluvoxamine, depending on the state of genetic polymorphism in each specific patient. If the fluvoxamine biotransformation rate is deviated by 50 % and more, a drug substitution recommendation is given. If slowing down the biotransformation of fluvoxamine by less than 50 %, a dose reduction recommendation is given. When accelerating the biotransformation of fluvoxamine by less than 50 %, a higher dose recommendation is given.EFFECT: disclosed method has high accuracy, information value and objectivity, since based on a method for reliable assessment of genetic apparatus and algorithms included in meta-analyzes of authoritative consortia when calculating similar values for other drugs.1 cl, 1 tbl
PROBLEM TO BE SOLVED: To make a user easily find an error of input observations through a medical diagnosis support device.SOLUTION: A GUI 102 is equipped with an input GUI for inputting respective image reading observations. An inference part 106 infers the probability that an object to be diagnosed is a predetermined diagnosis name based upon input information. Further, the degree (of contribution) that input information is affirmative or inaffirmative to each diagnosis name is calculated. A diagnosis name setting part 108 sets a diagnosis name of highest probability as a processing object diagnosis name based upon an inference result that the inference part 106 acquires. A factor selection part 110 selects input information (affirmative information ) with the highest degree that the processing object diagnosis name that the diagnosis name setting part 108 sets is affirmative and input information (inaffirmative information) having the largest degree that the processing object diagnosis name is inaffirmative. An emphasis display part 112 emphasizes and displays the input GUI of the image reading observation based upon the degree of contribution that the inference part 106 acquires.
Risk Summary

There is no information regarding the presence of trastuzumab in human milk, the effects on the breastfed infant, or the effects on milk production. Published data suggest human IgG is present in human milk but does not enter the neonatal and infant circulation in substantial amounts. Trastuzumab was present in the milk of lactating Cynomolgus monkeys but not associated with neonatal toxicity [see Data]. Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for Herceptin treatment and any potential adverse effects on the breastfed child from Herceptin or from the underlying maternal condition. This consideration should also take into account the trastuzumab wash out period of 7 months [see Clinical Pharmacology (12.3)].

Data

In lactating Cynomolgus monkeys, trastuzumab was present in breast milk at about 0.3% of maternal serum concentrations after pre- (beginning Gestation Day 120) and post-partum (through Post-partum Day 28) doses of 25 mg/kg administered twice weekly (25 times the recommended weekly human dose of 2 mg/kg of Herceptin). Infant monkeys with detectable serum levels of trastuzumab did not exhibit any adverse effects on growth or development from birth to 1 month of age.
BACKGROUND/AIM: Cytomegalovirus (CMV) is the most common congenital viral infection. Although most children with congenital CMV (approximately 85%-90%) are asymptomatic at birth, findings such as sensorineural hearing loss, microcephaly, and neurodevelopmental retardation can be observed during the follow-up. Among the brain magnetic resonance imaging (MRI) findings of CMV are white matter abnormalities, polymicrogyria, and periventricular calcification. Since a definitive diagnosis of congenital CMV cannot be made after the neonatal period, the identification of the associated phenotype is diagnostically important, but data are limited in patients who have been retrospectively diagnosed with congenital CMV infection. The aim of this study was to evaluate the short- and long-term neurological follow-up results of congenital CMV infections in a tertiary hospital.
MATERIALS AND METHODS: The neurological results of fifteen patients under the age of 18 years, who had a definitive diagnosis of congenital CMV infection and were followed up in a tertiary care hospital between 2011 and 2020, were retrospectively evaluated.
RESULTS: Ten of the patients in our study group were male. The mean age at presentation for neurological evaluation was 2.02 ± 1.54 months, with a median follow-up time of 36.3 months (range: 9.3-129.4 months). Neurological disorders detected during the long-term follow-up included cerebral palsy (46.7%), cognitive impairment (46.7%), epilepsy (40%), and sensorineural hearing loss (26.7%). The most common abnormality observed on MRI scans was white matter involvement (53.3%).
CONCLUSION: Early diagnosis and intervention are crucial in congenital CMV infection, as it commonly results in neurological involvement among the patients in our series. This preventable condition warrants further research regarding prenatal/neonatal screening.
Opioids: The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABA A sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation. 

Centrally Acting Agents: If diazepam is to be combined with other centrally acting agents, careful consideration should be given to the pharmacology of the agents employed particularly with compounds that may potentiate or be potentiated by the action of diazepam, such as phenothiazines, antipsychotics, anxiolytics/sedatives, hypnotics, anticonvulsants, narcotic analgesics, anesthetics, sedative antihistamines, narcotics, barbiturates, MAO inhibitors and other antidepressants. 

Alcohol: Concomitant use with alcohol is not recommended due to enhancement of the sedative effect. 

Antacids: Diazepam peak concentrations are 30% lower when antacids are administered concurrently. However, there is no effect on the extent of absorption. The lower peak concentrations appear due to a slower rate of absorption, with the time required to achieve peak concentrations on average 20 – 25 minutes greater in the presence of antacids. However, this difference was not statistically significant. 

Compounds Which Inhibit Certain Hepatic Enzymes: There is a potentially relevant interaction between diazepam and compounds which inhibit certain hepatic enzymes (particularly cytochrome P450 3A and 2C19). Data indicate that these compounds influence the pharmacokinetics of diazepam and may lead to increased and prolonged sedation. At present, this reaction is known to occur with cimetidine, ketoconazole, fluvoxamine, fluoxetine, and omeprazole. 

Phenytoin: There have also been reports that the metabolic elimination of phenytoin is decreased by diazepam.
BACKGROUND: This systematic review aimed to evaluate the performance of machine learning (ML) models in predicting post-treatment survival and disease progression outcomes, including recurrence and metastasis, in head and neck cancer (HNC) using clinicopathological structured data.
METHODS: A systematic search was conducted across the Medline, Scopus, Embase, Web of Science, and Google Scholar databases. The methodological characteristics and performance metrics of studies that developed and validated ML models were assessed. The risk of bias was evaluated using the Prediction model Risk Of Bias ASsessment Tool (PROBAST).
RESULTS: Out of 5,560 unique records, 34 articles were included. For survival outcome, the ML model outperformed the Cox proportional hazards model in time-to-event analyses for HNC, with a concordance index of 0.70-0.79 vs. 0.66-0.76, and for all sub-sites including oral cavity (0.73-0.89 vs. 0.69-0.77) and larynx (0.71-0.85 vs. 0.57-0.74). In binary classification analysis, the area under the receiver operating characteristics (AUROC) of ML models ranged from 0.75-0.97, with an F1-score of 0.65-0.89 for HNC; AUROC of 0.61-0.91 and F1-score of 0.58-0.86 for the oral cavity; and AUROC of 0.76-0.97 and F1-score of 0.63-0.92 for the larynx. Disease-specific survival outcomes showed higher performance than overall survival outcomes, but the performance of ML models did not differ between three- and five-year follow-up durations. For disease progression outcomes, no time-to-event metrics were reported for ML models. For binary classification of the oral cavity, the only evaluated subsite, the AUROC ranged from 0.67 to 0.97, with F1-scores between 0.53 and 0.89.
CONCLUSIONS: ML models have demonstrated considerable potential in predicting post-treatment survival and disease progression, consistently outperforming traditional linear models and their derived nomograms. Future research should incorporate more comprehensive treatment features, emphasize disease progression outcomes, and establish model generalizability through external validations and the use of multicenter datasets.